Scott A. Barman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Scott A. Barman has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Christiana Dimitropoulou
1 shared publicationCsaba Santai-Kis
1 shared publicationDavid J. R. Fulton
Department of Pharmacology and Toxicology Medical College of Georgia at Augusta University Augusta Georgia USA
1 shared publication- David J. R. Fulton
Augusta University
1 shared publication - Feng Chen
Nanjing Medical University
1 shared publication I.C. Ehrhart
Vascular Biology Center, Medical College of Georgia, Augusta, Georgia, 30912
1 shared publication
Latest Publications
- Open Access
- 17 July 2026
- Published by Wiley in Pulmonary Circulation
- Vol. 16 (3) , e70369
Evidence for PDZ‐Binding Kinase in Lung Disease With an Emphasis on PAH
Originally named T‐cell‐originated Lymphokine‐activated killer protein kinase (TOPK), PDZ‐Binding Kinase (PBK) is a serine/threonine kinase that is a member of the family of mitogen‐activated protein kinases (MAPKKs), which is overexpressed in lung cancer and interstitial pulmonary fibrosis (IPF). Along these lines, recent work also shows that PBK expression is upregulated in pulmonary arterial hypertension (PAH) in part due to the inappropriate proliferation of pulmonary arterial smooth muscle cells (PASMC), similar to the hyper‐proliferative cellular properties seen in both lung cancer and IPF. Genetic knock‐out of PBK as well as pharmacologically selective inhibitors of PBK improve PA remodeling and cardiopulmonary function. Further, PBK bound to the Protein Regulator of Cytokinesis 1 (PRC1) induces PRC1 phosphorylation and cytokinesis in PASMC, and thus, it is conjectured that PBK enhances PASMC proliferation via PRC1‐mediated cytokinesis, identifying a key mechanism which contributes to the pathologic pulmonary vascular remodeling that occurs in PAH. Towards this end, along with the already published studies showing that PBK is involved in both lung cancer and IPF, PBK‐mediated pulmonary vascular remodeling reveals a new signaling pathway in lung vascular disease and a novel mechanism of PASMC proliferation. Exploration of this signaling pathway will advance the utility of identifying novel therapeutic approaches targeting PBK‐mediated cytokinesis to reduce pulmonary vascular remodeling (as seen in PAH) and subsequently improve the morbidity and mortality associated with lung vascular disease. Collectively, the literature strongly suggests that PBK is a worthy and viable therapeutic target to pursue in the context of lung disease.
- 17 July 2026
- Published by Wiley in Pulmonary Circulation
- Vol. 16 (3) , e70369
Open AccessEvidence for PDZ‐Binding Kinase in Lung Disease With an Emphasis on PAH
Originally named T‐cell‐originated Lymphokine‐activated killer protein kinase (TOPK), PDZ‐Binding Kinase (PBK) is a serine/threonine kinase that is a member of the family of mitogen‐activated protein kinases (MAPKKs), which is overexpressed in lung cancer and interstitial pulmonary fibrosis (IPF). Along these lines, recent work also shows that PBK expression is upregulated in pulmonary arterial hypertension (PAH) in part due to the inappropriate proliferation of pulmonary arterial smooth muscle cells (PASMC), similar to the hyper‐proliferative cellular properties seen in both lung cancer and IPF. Genetic knock‐out of PBK as well as pharmacologically selective inhibitors of PBK improve PA remodeling and cardiopulmonary function. Further, PBK bound to the Protein Regulator of Cytokinesis 1 (PRC1) induces PRC1 phosphorylation and cytokinesis in PASMC, and thus, it is conjectured that PBK enhances PASMC proliferation via PRC1‐mediated cytokinesis, identifying a key mechanism which contributes to the pathologic pulmonary vascular remodeling that occurs in PAH. Towards this end, along with the already published studies showing that PBK is involved in both lung cancer and IPF, PBK‐mediated pulmonary vascular remodeling reveals a new signaling pathway in lung vascular disease and a novel mechanism of PASMC proliferation. Exploration of this signaling pathway will advance the utility of identifying novel therapeutic approaches targeting PBK‐mediated cytokinesis to reduce pulmonary vascular remodeling (as seen in PAH) and subsequently improve the morbidity and mortality associated with lung vascular disease. Collectively, the literature strongly suggests that PBK is a worthy and viable therapeutic target to pursue in the context of lung disease.
- 1 September 1997
- Published by Elsevier in Microvascular Research
- Vol. 54 (2) , 145-155
Endothelial Ectoenzyme Assays Estimate Perfused Capillary Surface Area in the Dog Lung
- 1 September 1997
- Published by Elsevier in Microvascular Research
- Vol. 54 (2) , 145-155
Endothelial Ectoenzyme Assays Estimate Perfused Capillary Surface Area in the Dog Lung
- 1 August 1997
- Published by American Physiological Society in Journal of Applied Physiology
- Vol. 83 (2) , 569-574
Pulmonary vasoreactivity to serotonin during hypoxia is modulated by ATP-sensitive potassium channels
Barman, Scott A. Pulmonary vasoreactivity to serotonin during hypoxia is modulated by ATP-sensitive potassium channels. J. Appl. Physiol. 83(2): 569–574, 1997.—The role of ATP-sensitive K+-channel modulation in the canine pulmonary vascular response to serotonin during hypoxia was determined in the isolated blood-perfused dog lung. Pulmonary vascular resistances and compliances were measured by using vascular occlusion techniques. Under normoxia, serotonin (10−5M) significantly increased precapillary and postcapillary resistances and pulmonary capillary pressure and decreased total vascular compliance by decreasing both microvascular and large-vessel compliances. During hypoxia, the effect of serotonin was potentiated on both precapillary and postcapillary resistance and capillary pressure, as well as on microvascular compliance and large-vessel compliance. Under normoxia, the ATP-sensitive K+-channel opener cromakalim (10−5M) inhibited the serotonergic response on postcapillary resistance and microvascular compliance, whereas during hypoxia cromakalim inhibited the potentiated effect of serotonin on both precapillary and postcapillary resistance, capillary pressure, and both microvascular and large-vessel compliances. These results indicate that canine pulmonary vasoreactivity to serotonin is heightened under hypoxic conditions and that ATP-sensitive K+channels modulate the pressor response to serotonin, an effect that is more pronounced during hypoxia.
- 1 August 1997
- Published by American Physiological Society in Journal of Applied Physiology
- Vol. 83 (2) , 569-574
Pulmonary vasoreactivity to serotonin during hypoxia is modulated by ATP-sensitive potassium channels
Barman, Scott A. Pulmonary vasoreactivity to serotonin during hypoxia is modulated by ATP-sensitive potassium channels. J. Appl. Physiol. 83(2): 569–574, 1997.—The role of ATP-sensitive K+-channel modulation in the canine pulmonary vascular response to serotonin during hypoxia was determined in the isolated blood-perfused dog lung. Pulmonary vascular resistances and compliances were measured by using vascular occlusion techniques. Under normoxia, serotonin (10−5M) significantly increased precapillary and postcapillary resistances and pulmonary capillary pressure and decreased total vascular compliance by decreasing both microvascular and large-vessel compliances. During hypoxia, the effect of serotonin was potentiated on both precapillary and postcapillary resistance and capillary pressure, as well as on microvascular compliance and large-vessel compliance. Under normoxia, the ATP-sensitive K+-channel opener cromakalim (10−5M) inhibited the serotonergic response on postcapillary resistance and microvascular compliance, whereas during hypoxia cromakalim inhibited the potentiated effect of serotonin on both precapillary and postcapillary resistance, capillary pressure, and both microvascular and large-vessel compliances. These results indicate that canine pulmonary vasoreactivity to serotonin is heightened under hypoxic conditions and that ATP-sensitive K+channels modulate the pressor response to serotonin, an effect that is more pronounced during hypoxia.